Global Small Molecule Drug Discovery Market 2018 Forecast to 2023 - The Versatility of Small Molecule Drugs is Drivng the Market - ResearchAndMarkets.com

DUBLIN--()--The "Global Small Molecule Drug Discovery Market - Segmented by Therapeutic Area, by Process Phase, and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The global small molecule drug discovery market is expected to witness a CAGR of 6.8% during the forecast period (2018-2023).

Small molecule drugs accounted for 84% of the total pharmaceutical industry revenue in 2014. In 2015, a total of 45 new molecular entities were approved in the United States, out of which 33 were small molecules. The versatility of small molecule drugs, which can range from global blockbusters to targeted therapies to orphan drugs, and their ability to be formulated into pills and tablets are driving the demand for these drugs.

There has been an increase in the number of Contract Development and Manufacturing Organizations (CDMO) entering the pharmaceutical industry. CDMOs that focus on the development of small molecules are experiencing a significant growth in the industry. In 2015, the revenues of Contract Research Organizations (CROs) and CDMOs, focusing on the development of small molecules, increased by 15-20%. CROs and CDMOs play a critical role in the drug discovery process as most of the key development activities are achieved by outsourcing them to contract organizations. The resultant rise in demand for small molecule drug will drive the market in forecast years.

Additionally, the dominance of small molecules in the market, small molecules in the treatment of chronic diseases, and the high R&D expenditure on small molecule drugs are fuelling the growth of global small molecule drug discovery market.

Key Developments in the Market

  • December 2017: Pfizer entered into an agreement to Develop and Commercialize CRESEMBA (isavuconazole) in China and Asia-Pacific Region.
  • December 2017: Teva Pharmaceutical launched a generic version of Viread that is used for the treatment of HIV-1 infection in adults and pediatric patients

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Company Profiles

  • Pfizer Inc
  • Bristol-Myers Squibb
  • Merck & Co.
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline
  • Astrazeneca
  • Johnson & Johnson
  • Gilead Sciences Inc.
  • Teva Pharmaceuticals

10. Future Outlook of the Market

For more information about this report visit https://www.researchandmarkets.com/research/fgl2jx/global_small?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery